المؤلفون: Wilcox JA; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Aizer AA; Department of Radiation Oncology, Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bale TA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Brandsma D; Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Brastianos PK; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chang S; Division of Neuro-Oncology, Department of Neurosurgery, University of San Francisco California, San Francisco, CA, USA., Daras M; Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA., Forsyth P; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Garzia L; Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada., Glantz M; Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA., Oliva ICG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kumthekar P; The Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA., Le Rhun E; Departments of Neurology and Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland., Nagpal S; Division of Neuro-Oncology, Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA., O'Brien B; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pentsova E; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Remsik J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Laboratory for Immunology of Metastatic Ecosystems, Center for Cancer Biology, VIB, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium., Rudà R; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.; Department of Neurology, Castelfranco Veneto and Treviso Hospitals, Castelfranco Veneto, Italy., Smalley I; Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Taylor MD; Division of Neurosurgery, Department of Surgery, Texas Children's Hospital, Houston, TX, USA Neuro-oncology Research Program, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine., Weller M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland., Wefel J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang JT; Department of Radiation Oncology, Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA., Young RJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boire AA; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

مؤلفون مشاركون: International Leptomeningeal Metastasis Collaborative

المصدر: Neuro-oncology [Neuro Oncol] 2024 Jun 21. Date of Electronic Publication: 2024 Jun 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE

المؤلفون: Budhu JA; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Neurology, Weill Cornell Medicine, Joan & Sanford I. Weill Medical College of Cornell University, New York, New York, USA., Chukwueke UN; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Jackson S; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Lee EQ; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., McFaline-Figueroa JR; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Willmarth N; American Brain Tumor Association, Chicago, Illinois, USA., Dalmage M; Division of Biological Sciences, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA., Kawachi I; Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Arons D; National Brain Tumor Society, Newton, Massachusetts, USA., Chang SM; Division of Neuro-Oncology, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, California, USA., Galanis E; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Hervey-Jumper SL; Department of Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, California, USA., Wen PY; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Porter AB; Department of Neurology, Mayo Clinic Cancer Center, Phoenix, Arizona, USA.

المصدر: Neuro-oncology [Neuro Oncol] 2024 Apr 05; Vol. 26 (4), pp. 596-608.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Brain Neoplasms*/therapy, Humans ; Ethnicity ; Medical Oncology ; Clinical Trials as Topic

المؤلفون: Neil AJ; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Chukwueke UN; Center for Neuro-Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Hoover N; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Marris SRN; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Rojas-Rudilla V; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Manning DK; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Mito JK; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Cibas ES; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

المصدر: Cancer cytopathology [Cancer Cytopathol] 2024 Apr; Vol. 132 (4), pp. 214-223. Date of Electronic Publication: 2023 Oct 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101499453 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1934-6638 (Electronic) Linking ISSN: 1934662X NLM ISO Abbreviation: Cancer Cytopathol Subsets: MEDLINE

مواضيع طبية MeSH: Cell-Free Nucleic Acids*/genetics , Neoplasms*/diagnostic imaging , Neoplasms*/genetics, Humans ; Mutation ; High-Throughput Nucleotide Sequencing/methods

المؤلفون: Rahman R; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Trippa L; Dana-Farber Cancer Institute, Boston, MA., Lee EQ; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Arrillaga-Romany I; Massachusetts General Hospital, Boston, MA., Fell G; Dana-Farber Cancer Institute, Boston, MA., Touat M; Brigham and Women's Hospital, Boston, MA.; Sorbonne Universite, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France., McCluskey C; Dana-Farber Cancer Institute, Boston, MA., Wiley J; Dana-Farber Cancer Institute, Boston, MA., Gaffey S; Dana-Farber Cancer Institute, Boston, MA., Drappatz J; University of Pittsburgh, Pittsburgh, PA., Welch MR; Division of Neuro-Oncology, Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian, New York, NY., Galanis E; Mayo Clinic, Rochester, MN., Ahluwalia MS; Miami Cancer Institute, Miami, FL., Colman H; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Nabors LB; University of Alabama at Birmingham, Birmingham, AL., Hepel J; Rhode Island Hospital, Providence, RI., Elinzano H; Rhode Island Hospital, Providence, RI., Schiff D; University of Virginia, Charlottesville, VA., Chukwueke UN; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Beroukhim R; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Nayak L; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., McFaline-Figueroa JR; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Batchelor TT; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Rinne ML; Dana-Farber Cancer Institute, Boston, MA., Kaley TJ; Memorial Sloan Kettering Cancer Center, New York, NY., Lu-Emerson C; Maine Medical Center, Portland, ME., Mellinghoff IK; Memorial Sloan Kettering Cancer Center, New York, NY., Bi WL; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Arnaout O; Brigham and Women's Hospital, Boston, MA., Peruzzi PP; Brigham and Women's Hospital, Boston, MA., Haas-Kogan D; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Tanguturi S; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Cagney D; Mater Private, Dublin, Ireland., Aizer A; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Doherty L; Dana-Farber Cancer Institute, Boston, MA., Lavallee M; Dana-Farber Cancer Institute, Boston, MA., Fisher-Longden B; Dana-Farber Cancer Institute, Boston, MA., Dowling S; Dana-Farber Cancer Institute, Boston, MA., Geduldig J; Dana-Farber Cancer Institute, Boston, MA., Watkinson F; Dana-Farber Cancer Institute, Boston, MA., Pisano W; Dana-Farber Cancer Institute, Boston, MA., Malinowski S; Dana-Farber Cancer Institute, Boston, MA., Ramkissoon S; Dana-Farber Cancer Institute, Boston, MA., Santagata S; Brigham and Women's Hospital, Boston, MA., Meredith DM; Brigham and Women's Hospital, Boston, MA., Chiocca EA; Brigham and Women's Hospital, Boston, MA., Reardon DA; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Alexander BM; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Ligon KL; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Wen PY; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 20; Vol. 41 (36), pp. 5524-5535. Date of Electronic Publication: 2023 Sep 18.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Glioblastoma*/pathology , Brain Neoplasms*/therapy, Humans ; Random Allocation ; Bayes Theorem ; ErbB Receptors/genetics ; Biomarkers

المؤلفون: Ryan CE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Zon RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Shouval R; Adult Bone Marrow Transplantation and Cellular Therapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, New York, USA., Kumar A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Sadrzadeh H; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nayak L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Frigault MJ; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA., Palomba ML; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Epstein-Peterson Z; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

المصدر: British journal of haematology [Br J Haematol] 2023 Dec; Vol. 203 (5), pp. 774-780. Date of Electronic Publication: 2023 Aug 16.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Mantle-Cell*/drug therapy , Receptors, Chimeric Antigen*/therapeutic use , Neurotoxicity Syndromes*/drug therapy, Adult ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Receptors, Antigen, T-Cell/therapeutic use ; T-Lymphocytes ; Treatment Outcome ; Antigens, CD19 ; Central Nervous System ; Cell- and Tissue-Based Therapy

المؤلفون: Michaelson NM; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA., Watsula A; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bakare-Okpala A; Department of Neurology, Weill Cornell Medicine, New York, NY, USA., Mohamadpour M; Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, C719, USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Budhu JA; Department of Neurology, Weill Cornell Medicine, New York, NY, USA. budhuj@mskcc.org.; Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, C719, USA. budhuj@mskcc.org.

المصدر: Current neurology and neuroscience reports [Curr Neurol Neurosci Rep] 2023 Dec; Vol. 23 (12), pp. 815-825. Date of Electronic Publication: 2023 Oct 27.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Current Science Inc Country of Publication: United States NLM ID: 100931790 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6293 (Electronic) Linking ISSN: 15284042 NLM ISO Abbreviation: Curr Neurol Neurosci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Central Nervous System Neoplasms*/diagnosis , Central Nervous System Neoplasms*/therapy, Humans ; Medical Oncology ; Forecasting

المؤلفون: Deng D; Massachusetts Institute of Technology, Harvard University, Boston, Massachusetts, USA., Hammoudeh L; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.; Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon, USA., Youssef G; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Chen YH; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts¸USA., Shin KY; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA., Lim-Fat MJ; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., McFaline-Figueroa JR; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Chukwueke UN; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Tanguturi S; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA., Reardon DA; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Lee EQ; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Nayak L; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Bi WL; Department of Neurosurgery, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA., Arnaout O; Department of Neurosurgery, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA., Ligon KL; Department of Pathology, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA., Wen PY; Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts¸ USA., Rahman R; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.

المصدر: Neuro-oncology advances [Neurooncol Adv] 2023 Jul 08; Vol. 5 (1), pp. vdad083. Date of Electronic Publication: 2023 Jul 08 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE

المؤلفون: Berger TR; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Wen PY; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts., Lang-Orsini M; Division of Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston., Chukwueke UN; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.

المصدر: JAMA oncology [JAMA Oncol] 2022 Oct 01; Vol. 8 (10), pp. 1493-1501.

نوع المنشور: Review; Journal Article

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Glioblastoma* , Glioma*/genetics , Glioma*/therapy , Oligodendroglioma*/genetics , Brain Neoplasms*/genetics , Brain Neoplasms*/therapy , Astrocytoma*/genetics , Central Nervous System Neoplasms*/therapy, Humans ; Adult ; Child ; Isocitrate Dehydrogenase/genetics ; World Health Organization ; Mutation

المؤلفون: Reihl SJ; University of California, San Francisco, Department of Neurosurgery, San Francisco, California,USA., Patil N; Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA.; University Health System, Research and Education Institute, Cleveland, Ohio, USA.; University Hospitals Health System, Research Health Analytics and Informatics, Cleveland, Ohio, USA., Morshed RA; University of California, San Francisco, Department of Neurosurgery, San Francisco, California,USA., Mehari M; University of California, San Francisco, Department of Neurosurgery, San Francisco, California,USA., Aabedi A; University of California, San Francisco, Department of Neurosurgery, San Francisco, California,USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA., Porter AB; Mayo Clinic, Division of Neuro-Oncology, Department of Neurology, Phoenix, Arizona, USA., Fontil V; University of California San Francisco, Division of General Internal Medicine, San Francisco, California, USA.; University of California San Francisco, Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital, San Francisco, California, USA., Cioffi G; Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, National Cancer Institute, Bethesda, Maryland,USA.; Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA., Waite K; Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, National Cancer Institute, Bethesda, Maryland,USA.; Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA., Kruchko C; Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA., Ostrom Q; Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA.; Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.; The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA., Barnholtz-Sloan J; Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois, USA.; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland,USA., Hervey-Jumper SL; University of California, San Francisco, Department of Neurosurgery, San Francisco, California,USA.

المصدر: Neuro-oncology [Neuro Oncol] 2022 Aug 01; Vol. 24 (8), pp. 1341-1349.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials as Topic* , Neoplasms*/therapy , Patient Selection*, Female ; Humans ; Male ; Minority Groups ; National Institutes of Health (U.S.) ; Research Design ; United States

المؤلفون: Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA. Electronic address: Ugonma_Chukwueke@DFCI.HARVARD.EDU., Hervey-Jumper S; Department of Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, 513 parnassus avenue, health science suite 814, San Francisco, CA 94143, USA., Porter A; Department of Neurology, Mayo Clinic Cancer Center, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA.

المصدر: Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2022 Feb; Vol. 36 (1), pp. e1-e8.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Health Science Country of Publication: United States NLM ID: 8709473 Publication Model: Print Cited Medium: Internet ISSN: 1558-1977 (Electronic) Linking ISSN: 08898588 NLM ISO Abbreviation: Hematol Oncol Clin North Am Subsets: MEDLINE

مواضيع طبية MeSH: Central Nervous System Neoplasms*/epidemiology , Central Nervous System Neoplasms*/therapy , Ethnicity*, Delivery of Health Care ; Humans ; Socioeconomic Factors ; United States